SIXTH AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • April 25th, 2011 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment and the Fifth Amendment, the “Support Agreement”);
RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • January 25th, 2019 • New York
This RECAPITALIZATION SUPPORT AGREEMENT is made and entered into as of January 25, 2019 (as amended, supplemented or otherwise modified from time to time, this “Agreement”), by and among TGLT S.A., a corporation (sociedad anónima) formed under the laws of Argentina (the “Company”), and the holders of the Notes (as defined below) listed on Schedule I hereto (including each holder of Notes that executes a joinder to this Agreement in the form attached hereto as Exhibit D) (each, a “Consenting Noteholder” and, together with the Company, the “Parties”).
RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • August 28th, 2014 • 21st Century Oncology Holdings, Inc. • Services-offices & clinics of doctors of medicine • New York
This RECAPITALIZATION SUPPORT AGREEMENT (this “Agreement”) is entered into as of July 29, 2014, by and among (i) 21st Century Oncology Investments, LLC (“Investments”), (ii) 21st Century Oncology Holdings, Inc. (“Holdings”), (iii) 21st Century Oncology, Inc. (“21C”) and each of their direct and indirect wholly owned subsidiaries that are obligors under the Senior Credit Agreement or the 21C Notes (each as defined in the Bridge Loan Facility) (collectively with Investments, Holdings and 21C, the “Company”), (iv) each of the undersigned holders of, or the investment advisor or manager to a beneficial or legal holder or holders of (and in such capacity having the power to bind such holder), certain indebtedness of the Company incurred under that certain Indenture (as amended to date, and as it may hereafter be amended, supplemented or modified from time to time, the “Subordinated Notes Indenture”) for the 9 7/8% Senior Subordinated Notes due 2017 (the “Subordinated Notes”), dated as of Ap
SECOND AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • December 17th, 2010 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment, the “Support Agreement”);
FIFTH AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • February 10th, 2011 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment, the Second Amendment, the Third Amendment and the Fourth Amendment, the “Support Agreement”);
FOURTH AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • January 28th, 2011 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment, the Second Amendment and the Third Amendment, the “Support Agreement”);
RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • November 2nd, 2010 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
This Recapitalization Support Agreement (the “Agreement”) dated as of October 29, 2010 between: (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other signatories hereto (each exercising its independent judgment and subject to Section 16(a), a “Consenting Noteholder” and collectively the “Consenting Noteholders”), with each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, addresses the principal aspects of the recapitalization of the Companies agreed to by the Companies and the Consenting Noteholders as described in Section 1 hereof (the “Recapitalization”, and the terms set out in Section 1 hereof being the “Recapitalization Terms”). The Recapitalization is to be effectuated pursuant to the Exchange Offer or as otherwise provided in this Agreement.
AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • December 2nd, 2010 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (the “Support Agreement”);
THIRD AGREEMENT TO AMEND THE RECAPITALIZATION SUPPORT AGREEMENTRecapitalization Support Agreement • January 13th, 2011 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • Ontario
WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment and the Second Amendment, the “Support Agreement”);
